Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Alflutinib in Patients With Advanced Non Small Cell Lung Cancer Who Progressed on Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Agent
Phase of Trial: Phase I/II
Latest Information Update: 18 Oct 2017
At a glance
- Drugs Alflutinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Allist Pharmaceuticals
- 18 Oct 2017 Status changed from not yet recruiting to recruiting, according to the results presented at the 18th World Conference on Lung Cancer.
- 18 Oct 2017 Results (n=17) presented at the 18th World Conference on Lung Cancer.
- 30 Nov 2016 New trial record